Skip to content

Carl Bjartmar is proposed as a new member to iCoat Medical’s Board of Directors

iCoat Medical’s nomination committee is proposing that Carl Bjartmar (born 1963) joins the company’s Board of Directors at an extraordinary general meeting on the 15th of December.

Carl Bjartmar is currently serving as the Chief Medical Officer at Ascelia Pharma AB.

Carl Bjartmar has a long and solid track record in late-stage orphan drug development. He has previously served in senior roles at large international pharmaceutical companies such as Lundbeck, Sanofi and Genzyme, where he gained extensive experience in clinical development, in particular the development of novel therapies for rare diseases. Carl was most recently before joining Ascelia, Chief Medical Officer for the Swedish biotech company Wilson Therapeutics, which was acquired by Alexion – now a part of AstraZeneca.

Carl Bjartmar holds a M.D. and Ph.D. from the University of Linköping.


A formal invite to the extraordinary general meeting will be distributed to all shareholders approximately three weeks before the meeting.